In MM however, loss of BAP1 expression detected by immunohistochemistry has shown contradictory prognostic implications, with some studies reporting improved patient outcomes with loss of BAP1 expression, suggesting a protective mechanism in disease development [14–16], and others reporting no change in patient survival [39–41]. This evidence concerns the gene BAP1 and Miyoshi myopathy.